KR102062262B1 - Wnt 경로 조절제로서의 퓨린 디온 - Google Patents

Wnt 경로 조절제로서의 퓨린 디온 Download PDF

Info

Publication number
KR102062262B1
KR102062262B1 KR1020157035961A KR20157035961A KR102062262B1 KR 102062262 B1 KR102062262 B1 KR 102062262B1 KR 1020157035961 A KR1020157035961 A KR 1020157035961A KR 20157035961 A KR20157035961 A KR 20157035961A KR 102062262 B1 KR102062262 B1 KR 102062262B1
Authority
KR
South Korea
Prior art keywords
delete delete
thiazol
cancer
phenyl
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157035961A
Other languages
English (en)
Korean (ko)
Other versions
KR20160029024A (ko
Inventor
호수예이
스테파니 엘리안 블랑샤드
안티사야마니 제야라지 두라이스와리
제니퍼 알람
바이크란트 아룬 에드솔
Original Assignee
에이전시 포 사이언스, 테크놀로지 앤드 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이전시 포 사이언스, 테크놀로지 앤드 리서치 filed Critical 에이전시 포 사이언스, 테크놀로지 앤드 리서치
Publication of KR20160029024A publication Critical patent/KR20160029024A/ko
Application granted granted Critical
Publication of KR102062262B1 publication Critical patent/KR102062262B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020157035961A 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온 Active KR102062262B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1309333.1 2013-05-23
GBGB1309333.1A GB201309333D0 (en) 2013-05-23 2013-05-23 Purine diones as WNT pathway modulators
PCT/SG2014/000217 WO2014189466A1 (en) 2013-05-23 2014-05-19 Purine diones as wnt pathway modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038593A Division KR102153989B1 (ko) 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온

Publications (2)

Publication Number Publication Date
KR20160029024A KR20160029024A (ko) 2016-03-14
KR102062262B1 true KR102062262B1 (ko) 2020-01-03

Family

ID=48784655

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157035961A Active KR102062262B1 (ko) 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온
KR1020197038593A Active KR102153989B1 (ko) 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197038593A Active KR102153989B1 (ko) 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온

Country Status (13)

Country Link
US (6) US9926320B2 (enExample)
EP (1) EP2999699B1 (enExample)
JP (1) JP6506742B2 (enExample)
KR (2) KR102062262B1 (enExample)
CN (2) CN105452248A (enExample)
AU (2) AU2014269134B2 (enExample)
BR (1) BR112015029182B1 (enExample)
CA (1) CA2912757C (enExample)
DK (1) DK2999699T3 (enExample)
ES (1) ES2802923T3 (enExample)
GB (1) GB201309333D0 (enExample)
SG (1) SG11201509593TA (enExample)
WO (1) WO2014189466A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
GB201322334D0 (en) 2013-12-17 2014-01-29 Agency Science Tech & Res Maleimide derivatives as modulators of WNT pathway
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
PT3193880T (pt) 2014-09-19 2020-06-19 Lilly Co Eli Inibição do canal iónico receptor de potencial transitório a1
CN105440034B (zh) * 2015-11-16 2017-08-15 山东罗欣药业集团股份有限公司 一种利格列汀及其中间体的制备方法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN106632332B (zh) * 2016-09-26 2018-07-06 杭州新博思生物医药有限公司 一种伊曲茶碱的制备方法
WO2019054941A1 (en) 2017-09-14 2019-03-21 Agency For Science, Technology And Research MODULATORS OF THE WNT PATH
BR112020014584A2 (pt) 2018-01-31 2020-12-01 Eli Lilly And Company inibição do canal iônico do receptor de potencial transitório a1
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
CN114072131B (zh) * 2019-05-22 2024-03-19 新加坡科技研究局 口服制剂、其制备方法及其用途
WO2020236078A1 (en) * 2019-05-22 2020-11-26 Agency For Science, Technology And Research Pharmaceutical combination
CN114072408B (zh) * 2019-07-08 2023-05-12 南京明德新药研发有限公司 作为porcupine抑制剂的化合物及其应用
JP2023511039A (ja) * 2020-01-08 2023-03-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 組み合わせ療法
BR112023025403A2 (pt) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
WO2023072263A1 (zh) 2021-10-29 2023-05-04 南京明德新药研发有限公司 5-取代的吡啶-2(1h)-酮类化合物及其应用
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN120737092B (zh) * 2025-09-05 2025-11-14 利诚检测认证集团股份有限公司 别嘌醇半抗原及其制备方法、人工抗原、抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010075353A1 (en) * 2008-12-22 2010-07-01 Hydra Biosciences, Inc. Compositions useful for treating disorders related to trpa1
WO2011042798A1 (en) * 2009-10-08 2011-04-14 Incozen Therapeutics Pvt. Ltd. Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
US20120316136A1 (en) * 2011-06-13 2012-12-13 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2013023102A1 (en) * 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
ES2436225T3 (es) 2005-12-22 2013-12-27 Hydra Biosciences, Inc. Inhibidores TRPA1 para tratamiento del dolor
EP3663295A1 (en) * 2007-06-22 2020-06-10 Eli Lilly And Co. 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US20120046305A1 (en) 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2655377B1 (en) * 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
JP5659098B2 (ja) * 2011-07-19 2015-01-28 株式会社東芝 半導体装置の製造方法
WO2013014597A1 (en) * 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
AU2012308570B2 (en) * 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
AU2013259294B2 (en) 2012-05-11 2017-04-06 Synchronicity Pharma, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010075353A1 (en) * 2008-12-22 2010-07-01 Hydra Biosciences, Inc. Compositions useful for treating disorders related to trpa1
WO2011042798A1 (en) * 2009-10-08 2011-04-14 Incozen Therapeutics Pvt. Ltd. Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
US20120316136A1 (en) * 2011-06-13 2012-12-13 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2013023102A1 (en) * 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1

Also Published As

Publication number Publication date
CN109776537A (zh) 2019-05-21
AU2017219132B2 (en) 2019-04-18
AU2014269134B2 (en) 2017-06-15
GB201309333D0 (en) 2013-07-10
DK2999699T3 (da) 2020-07-13
US10526335B2 (en) 2020-01-07
US20200190086A1 (en) 2020-06-18
BR112015029182A2 (pt) 2017-07-25
KR20160029024A (ko) 2016-03-14
US20180170932A1 (en) 2018-06-21
US20230174533A1 (en) 2023-06-08
US20170334912A1 (en) 2017-11-23
EP2999699A4 (en) 2016-10-26
ES2802923T3 (es) 2021-01-21
EP2999699A1 (en) 2016-03-30
CA2912757C (en) 2021-11-30
US20210155623A1 (en) 2021-05-27
CN105452248A (zh) 2016-03-30
JP2016519165A (ja) 2016-06-30
AU2014269134A1 (en) 2015-12-10
CN109776537B (zh) 2021-12-14
BR112015029182B1 (pt) 2023-10-03
WO2014189466A1 (en) 2014-11-27
US20160090386A1 (en) 2016-03-31
KR20200000504A (ko) 2020-01-02
BR112015029182A8 (pt) 2020-03-17
KR102153989B1 (ko) 2020-09-09
US10472360B2 (en) 2019-11-12
US10844063B2 (en) 2020-11-24
US9926320B2 (en) 2018-03-27
JP6506742B2 (ja) 2019-04-24
SG11201509593TA (en) 2015-12-30
EP2999699B1 (en) 2020-04-29
AU2017219132A1 (en) 2017-09-14
US11555037B2 (en) 2023-01-17
CA2912757A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
KR102062262B1 (ko) Wnt 경로 조절제로서의 퓨린 디온
CN114555588B (zh) 作为axl抑制剂的喹唑啉类化合物
US11434245B2 (en) WNT pathway modulators
KR20040004705A (ko) 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
JP2010521458A (ja) 接着斑キナーゼのインヒビター
US9981964B2 (en) Maleimide derivatives as modulators of wnt pathway
KR20050038010A (ko) 2-(3-아미노아릴)아미노-4-아릴-티아졸 및 ｃ-ｋｉｔ억제제로서의 이의 용도
CN101289444B (zh) 一种嘧啶衍生物及其医药用途
WO2014175832A1 (en) Wnt pathway modulators
WO2015187094A1 (en) Phthalimide derivatives as modulators of wnt pathway
Class et al. Patent application title: Purine Diones As Wnt Pathway Modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190228

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190722

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190722

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190429

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190927

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190828

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190722

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190429

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191227

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191227

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191227

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221116

Start annual number: 4

End annual number: 4